Changes of Neurotransmitters in the Striatum of MPTP-induced Wild-type and A53T Transgenic Mouse Parkinson's Disease Models

doi:10.19803/j.1672-8629.2021.04.04

Abstract

Abstract: Objective To explore the changes of such neurotransmitters as dopamine in the striatum of mouse models with Parkinson's disease (PD). Methods An acute PD model of A53T transgenic mice and a chronic PD model of wild-type mice were induced via intraperitoneal injection of probenecid and subcutaneous injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). High-performance liquid chromatography (HPLC) was used to detect the changes of neurotransmitters in the mouse striatum. Results HPLC results showed that MPTP could induce an decrease of dopamine (DA), dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) in the striatum, and an increase of dihydroxy phenylacetaldehyde (DOPAL). But the contents of serotonin (5-HT) and norepinephrine (NE) did not change significantly. Conclusion MPTP can induce a decrease in the level of DA transmitters and an increase in the content of its toxic metabolite DOPAL, thereby promoting the occurrence and development of PD.

Key words: Parkinson's disease, MPTP, striatum, A53T, neurotransmitter

CLC Number:

R994.1

WANG Shuo, WEN Lu, ZHANG Chenglu, WANG Ruxuan, CHEN Naihong, YUAN Yuhe. Changes of Neurotransmitters in the Striatum of MPTP-induced Wild-type and A53T Transgenic Mouse Parkinson's Disease Models[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 315-319.

References

[1] Teri Capriotti.Parkinson disease[J]. Home Healthcare Now, 2016, 34(6): 300-307.
[2] Alves G, Forsaa EB, Pedersen KF, et al.epidemiology of parkinson's disease[J]. J Neural Transm (Vienna), 2017, 124(8): 901-905.
[3] Abeliovich A, Rhinn H.Parkinson's disease: guilt by genetic association[J]. Nature, 2016, 533(7601): 40-41.
[4] Henrich MT, Geibl FF, Lee B, et al.A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia[J]. Acta Neuropathol Commun, 2018, 6(1): 39.
[5] Zhou TT, Zhang QS.Effects of bibenzyl compound (20C) from gastrodia elata on MPTP/p-induced mice and mechanism[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(11): 753-757,772.
[6] Zhang QS, Chen Y.Parkinsonian lesion in rat induced by rotenone and its possible mechanism[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(9): 513-517.
[7] Mattammal MB, Haring JH, Chung HD, et al.An endogenous dopaminergic neurotoxin: implication for Parkinson's disease[J]. Neurodegeneration, 1995, 4(3): 271-281.
[8] Jackson-Lewis V, Przedborski S.Protocol for the MPTP mouse model of parkinson's disease[J]. Nature Protocols, 2007, 2(1): 141-151.
[9] Masato A, Plotegher N, Boassa D, et al.Impaired dopamine metabolism in Parkinson's disease pathogenesis[J]. Molecular Neurodegeneration, 2019, 14(1): 35.
[10] Marchitti SA, Deitrich RA, Vasiliou V.Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase[J]. Pharmacological Reviews, 2007, 59(2): 125-150.
[11] Lima Vanderlei de A, Do Nascimento LA, Eliezer D, et al. Role of Parkinson's disease-linked mutations and N-terminal acetylation on the oligomerization of α-synuclein induced by 3,4-dihydroxyphenylacetaldehyde[J]. ACS Chemical Neuroscience, 2019, 10(1): 690-703.
[12] Burke WJ, Li SW, Williams EA, et al.3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis[J]. Brain Research, 2003, 989(2): 205-213.
[13] Goldstein DS, Sullivan P, Cooney A, et al.Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetal- dehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease[J]. Journal of Neurochemistry, 2012, 123(6): 932-943.
[14] Casida JE, Ford B, Jinsmaa Y, et al.Benomyl, aldehyde dehy- drogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease[J]. Chemical Research in Toxicology, 2014, 27(8): 1359-1361.
[15] Goldstein DS.The catecholaldehyde hypothesis: where MAO fits in[J]. Journal of Neural Transmission, 2020, 127(2): 169-177.